Hemogenyx Pharmaceuticals PLC Announces Further re. Grant of Options
Back to Newsroom
Mentioned in this Article

Hemogenyx Pharmaceuticals PLC Announces Further re. Grant of Options

Tuesday, September 22, 2020 8:20 AM
Share this article now
Topic:
Company Update
Hemogenyx Pharmaceuticals PLC

LONDON, UK / ACCESSWIRE / September 22, 2020 / On 21 August 2020, the Company announced that the Directors had granted the Company's co-founder and CEO Dr Vladislav Sandler options over a total of 5,000,000 ordinary shares of 1p each in the capital of the Company ("Share Options"). The Directors have now resolved to adjust the exercise price of the Share Options to 9p to reflect the Company's share price at the time of the grant. All other details regarding the grant of the Share Options remain the same.

Enquiries:

Hemogenyx Pharmaceuticals plc

https://hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

[email protected]

Peter Redmond, Director

[email protected]

   

SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Soltan Tagiev

 
   

Peterhouse Capital Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMR") and persons closely associated with them ("PCA"):

1.

Details of PDMR/person closely associated with them

a)

Name

Dr Vladislav Sandler

b)

Position/status

CEO, Executive Director

c)

Initial notification/
amendment

Amendment to prior notification no. 00117904

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Options over ordinary shares of 1p of Hemogenyx Pharmaceuticals plc
Identification code GB00BYX3WZ24

b)

Nature of the transaction

Grant of options

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.09

5,000,000

 

 

d)

Aggregated information

- Aggregated volume

- Price

Price(s)

Volume(s)

N/A - variable

5,000,000

e)

Date of the transaction

20/08/2020

f)

Place of the transaction

Outside of a trading venue

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

Back to Newsroom
Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions